Harikumar et al. reported that RES synergized the effect of gemcitabine on human pancreatic cancer cells in vitro and in vivo by: (a) inhibiting the NF-κB pathway; (b) inhibiting Bcl-2, Bcl-xL, COX-2, cyclin D1, MMP-9, and VEGF expression; and (c) down-regulating the production of markers for angiogenesis (CD31) and cellular proliferation (Ki-67). Here, NFKB1 is linked to familial pancreatic carcinoma.